Patient demographic, clinical and surgical characteristics stratified by the interval between imaging and surgery
| Patient characteristics . | 0 to <30 days (n = 228) . | 30 to <60 days (n = 242) . | 60–180 days (n = 152) . | P-value . |
|---|---|---|---|---|
| Age (years), median (IQR p25–p75) | 69.0 (63.0–74.0) | 70.0 (63.0–75.0) | 69.0 (61.0–74.0) | 0.367a |
| Gender, n (%) | 0.740 | |||
| Female | 70 (30.7) | 81 (33.5) | 46 (30.3) | |
| Male | 158 (69.3) | 161 (66.5) | 106 (69.7) | |
| BMI (kg/m2), median (IQR p25–p75) | 26.2 (23.5–30.1) | 26.4 (23.2–30.5) | 26.5 (23.8–30.1) | 0.931a |
| Missing, n (%) | 11 (4.8) | 18 (7.4) | 11 (7.2) | |
| FEV1 (% predicted), median (IQR p25–p75) | 0.9 (0.7–1.0) | 0.9 (0.7–1.0) | 0.9 (0.8–1.0) | 0.439a |
| Missing, n (%) | 27 (11.8) | 27 (11.2) | 14 (9.2) | |
| Total chest CT nodule size (cm), median (IQR p25–p75) | 1.6 (1.2–2.2) | 1.7 (1.2–2.2) | 1.5 (1.1–2.1) | 0.210a |
| Solid component nodule size (cm), median (IQR p25–p75) | 0.8 (0.0–1.2) | 0.8 (0.4–1.4) | 0.8 (0.3–1.1) | 0.359a |
| CT nodule characteristic, n (%) | 0.541 | |||
| Ground-glass | 62 (27.2) | 51 (21.1) | 33 (21.7) | |
| Part-solid | 105 (46.1) | 116 (47.9) | 72 (47.4) | |
| Solid | 61 (26.8) | 75 (31.0) | 47 (30.9) | |
| PET–CT, n (%) | 0.019 | |||
| Yes | 127 (55.7) | 157 (64.9) | 105 (69.1) | |
| No | 101 (44.3) | 85 (35.1) | 47 (30.9) | |
| Lesion location, n (%) | 0.296 | |||
| RUL | 84 (36.8) | 83 (34.3) | 63 (41.4) | |
| ML | 11 (4.8) | 14 (5.8) | 7 (4.6) | |
| RLL | 51 (22.4) | 48 (19.8) | 20 (13.2) | |
| LUL | 47 (20.6) | 66 (27.3) | 35 (23.0) | |
| LLL | 35 (15.4) | 31 (12.8) | 27 (17.8) | |
| Surgical procedure, n (%) | 0.127 | |||
| Wedge resection | 121 (53.1) | 114 (47.1) | 64 (42.1) | |
| Segmentectomy | 52 (22.8) | 75 (31.0) | 51 (33.6) | |
| Lobectomy | 55 (24.1) | 53 (21.9) | 37 (24.3) | |
| Histology nodule, n (%) | 0.126 | |||
| Adenocarcinoma | 211 (92.5) | 221 (91.3) | 129 (84.9) | |
| Squamous cell carcinoma | 9 (3.9) | 14 (5.8) | 11 (7.2) | |
| Carcinoid | 4 (1.8) | 3 (1.2) | 8 (5.3) | |
| Others | 4 (1.8) | 4 (1.7) | 4 (2.6) | |
| Number of lymph nodes examined, median (IQR p25–p75) | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) | 4.0 (2.0–7.0) | 0.640 |
| Pathological N stage, n (%) | 0.073 | |||
| Nx | 26 (11.4) | 13 (5.4) | 18 (11.8) | |
| N0 | 194 (85.1) | 222 (91.7) | 131 (86.2) | |
| N1 | 3 (1.3) | 5 (2.1) | 3 (2.0) | |
| N2 | 5 (2.2) | 2 (0.8) | 0 (0.0) |
| Patient characteristics . | 0 to <30 days (n = 228) . | 30 to <60 days (n = 242) . | 60–180 days (n = 152) . | P-value . |
|---|---|---|---|---|
| Age (years), median (IQR p25–p75) | 69.0 (63.0–74.0) | 70.0 (63.0–75.0) | 69.0 (61.0–74.0) | 0.367a |
| Gender, n (%) | 0.740 | |||
| Female | 70 (30.7) | 81 (33.5) | 46 (30.3) | |
| Male | 158 (69.3) | 161 (66.5) | 106 (69.7) | |
| BMI (kg/m2), median (IQR p25–p75) | 26.2 (23.5–30.1) | 26.4 (23.2–30.5) | 26.5 (23.8–30.1) | 0.931a |
| Missing, n (%) | 11 (4.8) | 18 (7.4) | 11 (7.2) | |
| FEV1 (% predicted), median (IQR p25–p75) | 0.9 (0.7–1.0) | 0.9 (0.7–1.0) | 0.9 (0.8–1.0) | 0.439a |
| Missing, n (%) | 27 (11.8) | 27 (11.2) | 14 (9.2) | |
| Total chest CT nodule size (cm), median (IQR p25–p75) | 1.6 (1.2–2.2) | 1.7 (1.2–2.2) | 1.5 (1.1–2.1) | 0.210a |
| Solid component nodule size (cm), median (IQR p25–p75) | 0.8 (0.0–1.2) | 0.8 (0.4–1.4) | 0.8 (0.3–1.1) | 0.359a |
| CT nodule characteristic, n (%) | 0.541 | |||
| Ground-glass | 62 (27.2) | 51 (21.1) | 33 (21.7) | |
| Part-solid | 105 (46.1) | 116 (47.9) | 72 (47.4) | |
| Solid | 61 (26.8) | 75 (31.0) | 47 (30.9) | |
| PET–CT, n (%) | 0.019 | |||
| Yes | 127 (55.7) | 157 (64.9) | 105 (69.1) | |
| No | 101 (44.3) | 85 (35.1) | 47 (30.9) | |
| Lesion location, n (%) | 0.296 | |||
| RUL | 84 (36.8) | 83 (34.3) | 63 (41.4) | |
| ML | 11 (4.8) | 14 (5.8) | 7 (4.6) | |
| RLL | 51 (22.4) | 48 (19.8) | 20 (13.2) | |
| LUL | 47 (20.6) | 66 (27.3) | 35 (23.0) | |
| LLL | 35 (15.4) | 31 (12.8) | 27 (17.8) | |
| Surgical procedure, n (%) | 0.127 | |||
| Wedge resection | 121 (53.1) | 114 (47.1) | 64 (42.1) | |
| Segmentectomy | 52 (22.8) | 75 (31.0) | 51 (33.6) | |
| Lobectomy | 55 (24.1) | 53 (21.9) | 37 (24.3) | |
| Histology nodule, n (%) | 0.126 | |||
| Adenocarcinoma | 211 (92.5) | 221 (91.3) | 129 (84.9) | |
| Squamous cell carcinoma | 9 (3.9) | 14 (5.8) | 11 (7.2) | |
| Carcinoid | 4 (1.8) | 3 (1.2) | 8 (5.3) | |
| Others | 4 (1.8) | 4 (1.7) | 4 (2.6) | |
| Number of lymph nodes examined, median (IQR p25–p75) | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) | 4.0 (2.0–7.0) | 0.640 |
| Pathological N stage, n (%) | 0.073 | |||
| Nx | 26 (11.4) | 13 (5.4) | 18 (11.8) | |
| N0 | 194 (85.1) | 222 (91.7) | 131 (86.2) | |
| N1 | 3 (1.3) | 5 (2.1) | 3 (2.0) | |
| N2 | 5 (2.2) | 2 (0.8) | 0 (0.0) |
Significance determined using Kruskal–Wallis test, due to non-normal distribution of the data.
BMI: body mass index; CT: computed tomography; FEV1: forced expiratory volume in 1 s; IQR: interquartile range; LLL: left lower lobe; LUL: left upper lobe; ML: middle lobe; PET–CT: positron emission tomography–computed tomography; RLL: right lower lobe; RUL: right upper lobe.
Patient demographic, clinical and surgical characteristics stratified by the interval between imaging and surgery
| Patient characteristics . | 0 to <30 days (n = 228) . | 30 to <60 days (n = 242) . | 60–180 days (n = 152) . | P-value . |
|---|---|---|---|---|
| Age (years), median (IQR p25–p75) | 69.0 (63.0–74.0) | 70.0 (63.0–75.0) | 69.0 (61.0–74.0) | 0.367a |
| Gender, n (%) | 0.740 | |||
| Female | 70 (30.7) | 81 (33.5) | 46 (30.3) | |
| Male | 158 (69.3) | 161 (66.5) | 106 (69.7) | |
| BMI (kg/m2), median (IQR p25–p75) | 26.2 (23.5–30.1) | 26.4 (23.2–30.5) | 26.5 (23.8–30.1) | 0.931a |
| Missing, n (%) | 11 (4.8) | 18 (7.4) | 11 (7.2) | |
| FEV1 (% predicted), median (IQR p25–p75) | 0.9 (0.7–1.0) | 0.9 (0.7–1.0) | 0.9 (0.8–1.0) | 0.439a |
| Missing, n (%) | 27 (11.8) | 27 (11.2) | 14 (9.2) | |
| Total chest CT nodule size (cm), median (IQR p25–p75) | 1.6 (1.2–2.2) | 1.7 (1.2–2.2) | 1.5 (1.1–2.1) | 0.210a |
| Solid component nodule size (cm), median (IQR p25–p75) | 0.8 (0.0–1.2) | 0.8 (0.4–1.4) | 0.8 (0.3–1.1) | 0.359a |
| CT nodule characteristic, n (%) | 0.541 | |||
| Ground-glass | 62 (27.2) | 51 (21.1) | 33 (21.7) | |
| Part-solid | 105 (46.1) | 116 (47.9) | 72 (47.4) | |
| Solid | 61 (26.8) | 75 (31.0) | 47 (30.9) | |
| PET–CT, n (%) | 0.019 | |||
| Yes | 127 (55.7) | 157 (64.9) | 105 (69.1) | |
| No | 101 (44.3) | 85 (35.1) | 47 (30.9) | |
| Lesion location, n (%) | 0.296 | |||
| RUL | 84 (36.8) | 83 (34.3) | 63 (41.4) | |
| ML | 11 (4.8) | 14 (5.8) | 7 (4.6) | |
| RLL | 51 (22.4) | 48 (19.8) | 20 (13.2) | |
| LUL | 47 (20.6) | 66 (27.3) | 35 (23.0) | |
| LLL | 35 (15.4) | 31 (12.8) | 27 (17.8) | |
| Surgical procedure, n (%) | 0.127 | |||
| Wedge resection | 121 (53.1) | 114 (47.1) | 64 (42.1) | |
| Segmentectomy | 52 (22.8) | 75 (31.0) | 51 (33.6) | |
| Lobectomy | 55 (24.1) | 53 (21.9) | 37 (24.3) | |
| Histology nodule, n (%) | 0.126 | |||
| Adenocarcinoma | 211 (92.5) | 221 (91.3) | 129 (84.9) | |
| Squamous cell carcinoma | 9 (3.9) | 14 (5.8) | 11 (7.2) | |
| Carcinoid | 4 (1.8) | 3 (1.2) | 8 (5.3) | |
| Others | 4 (1.8) | 4 (1.7) | 4 (2.6) | |
| Number of lymph nodes examined, median (IQR p25–p75) | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) | 4.0 (2.0–7.0) | 0.640 |
| Pathological N stage, n (%) | 0.073 | |||
| Nx | 26 (11.4) | 13 (5.4) | 18 (11.8) | |
| N0 | 194 (85.1) | 222 (91.7) | 131 (86.2) | |
| N1 | 3 (1.3) | 5 (2.1) | 3 (2.0) | |
| N2 | 5 (2.2) | 2 (0.8) | 0 (0.0) |
| Patient characteristics . | 0 to <30 days (n = 228) . | 30 to <60 days (n = 242) . | 60–180 days (n = 152) . | P-value . |
|---|---|---|---|---|
| Age (years), median (IQR p25–p75) | 69.0 (63.0–74.0) | 70.0 (63.0–75.0) | 69.0 (61.0–74.0) | 0.367a |
| Gender, n (%) | 0.740 | |||
| Female | 70 (30.7) | 81 (33.5) | 46 (30.3) | |
| Male | 158 (69.3) | 161 (66.5) | 106 (69.7) | |
| BMI (kg/m2), median (IQR p25–p75) | 26.2 (23.5–30.1) | 26.4 (23.2–30.5) | 26.5 (23.8–30.1) | 0.931a |
| Missing, n (%) | 11 (4.8) | 18 (7.4) | 11 (7.2) | |
| FEV1 (% predicted), median (IQR p25–p75) | 0.9 (0.7–1.0) | 0.9 (0.7–1.0) | 0.9 (0.8–1.0) | 0.439a |
| Missing, n (%) | 27 (11.8) | 27 (11.2) | 14 (9.2) | |
| Total chest CT nodule size (cm), median (IQR p25–p75) | 1.6 (1.2–2.2) | 1.7 (1.2–2.2) | 1.5 (1.1–2.1) | 0.210a |
| Solid component nodule size (cm), median (IQR p25–p75) | 0.8 (0.0–1.2) | 0.8 (0.4–1.4) | 0.8 (0.3–1.1) | 0.359a |
| CT nodule characteristic, n (%) | 0.541 | |||
| Ground-glass | 62 (27.2) | 51 (21.1) | 33 (21.7) | |
| Part-solid | 105 (46.1) | 116 (47.9) | 72 (47.4) | |
| Solid | 61 (26.8) | 75 (31.0) | 47 (30.9) | |
| PET–CT, n (%) | 0.019 | |||
| Yes | 127 (55.7) | 157 (64.9) | 105 (69.1) | |
| No | 101 (44.3) | 85 (35.1) | 47 (30.9) | |
| Lesion location, n (%) | 0.296 | |||
| RUL | 84 (36.8) | 83 (34.3) | 63 (41.4) | |
| ML | 11 (4.8) | 14 (5.8) | 7 (4.6) | |
| RLL | 51 (22.4) | 48 (19.8) | 20 (13.2) | |
| LUL | 47 (20.6) | 66 (27.3) | 35 (23.0) | |
| LLL | 35 (15.4) | 31 (12.8) | 27 (17.8) | |
| Surgical procedure, n (%) | 0.127 | |||
| Wedge resection | 121 (53.1) | 114 (47.1) | 64 (42.1) | |
| Segmentectomy | 52 (22.8) | 75 (31.0) | 51 (33.6) | |
| Lobectomy | 55 (24.1) | 53 (21.9) | 37 (24.3) | |
| Histology nodule, n (%) | 0.126 | |||
| Adenocarcinoma | 211 (92.5) | 221 (91.3) | 129 (84.9) | |
| Squamous cell carcinoma | 9 (3.9) | 14 (5.8) | 11 (7.2) | |
| Carcinoid | 4 (1.8) | 3 (1.2) | 8 (5.3) | |
| Others | 4 (1.8) | 4 (1.7) | 4 (2.6) | |
| Number of lymph nodes examined, median (IQR p25–p75) | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) | 4.0 (2.0–7.0) | 0.640 |
| Pathological N stage, n (%) | 0.073 | |||
| Nx | 26 (11.4) | 13 (5.4) | 18 (11.8) | |
| N0 | 194 (85.1) | 222 (91.7) | 131 (86.2) | |
| N1 | 3 (1.3) | 5 (2.1) | 3 (2.0) | |
| N2 | 5 (2.2) | 2 (0.8) | 0 (0.0) |
Significance determined using Kruskal–Wallis test, due to non-normal distribution of the data.
BMI: body mass index; CT: computed tomography; FEV1: forced expiratory volume in 1 s; IQR: interquartile range; LLL: left lower lobe; LUL: left upper lobe; ML: middle lobe; PET–CT: positron emission tomography–computed tomography; RLL: right lower lobe; RUL: right upper lobe.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
